Lab study looks at what makes brain tumor cells respond to a drug called ONC212
Original title: KATP Channel Expression Determines ONC212 Sensitivity via Mitochondrial Dysfunction and PERK/ATF4/CHOP Activation in Glioblastoma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done on cells in a dish, not in people.
The short version
In a lab dish, a drug called ONC212 killed glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary cells, and a tiny channel on the cells changed how well it worked.
What was studied. Researchers tested a drug called ONC212 on human glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary cells grown in a lab. They also tested it on normal brain support cells. Then they changed the level of a cell channel called KATP to see if it changed how well the drug worked.
What they found. ONC212 harmed the tumor cells more than the normal cells. The tumor cells with the most KATP channels were hit the hardest. The drug damaged the parts of the cell that make energy, so the cells ran short of fuel and started to die. When the researchers blocked or removed KATP, the drug worked even harder. When they turned KATP on, the cells were protected.
What this means, and what it doesn't
What it could mean: This is early science that hints at a way to make ONC212 work better against glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary. It also raises the idea that KATP levels could one day help show who might respond. Right now it does not change any treatment choice.
What it doesn't mean: This does not mean there is a new treatment. The work was done on cells in a dish, not in people. No patient was treated in this study. ONC212 is not approved or standard care for glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary. Many things that work on cells in a dish never work in people. This is not a promise of a cure, and it is a long way from everyday care.
Source: PubMed, July 1, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.